CD79A and COVID-19: Influenza virus–vectored COVID-19 vaccine expressing SARS-CoV-2 S-RBD was approved under EUA in China, although it showed weak immune responses, with 10% serum antibody, 12% nasal IgA antibody, and 46% antigen-specific T cell responses after two doses in phase 2 trials (23).